Navigation Links
Notre Dame researchers develop system that uses a big data approach to personalized healthcare
Date:7/25/2013

University of Notre Dame researchers have developed a computer-aided method that uses electronic medical records to offer the promise of rapid advances toward personalized health care, disease management and wellness.

Notre Dame computer science professor Nitesh V. Chawla and his doctoral student, Darcy A. Davis, developed the system called Collaborative Assessment and Recommendation Engine (CARE) for personalized disease risk predictions and wellbeing.

"The potential for 'personalizing' health care from a disease prevention, disease management and therapeutics perspective is increasing," Chawla said. "Health care informatics and advanced analytics, or data science, may contribute to this shift from population-based evidence for health care decision-making to the fusion of population and individual based evidence in health care. The key question is: how to leverage health population data to drive patient-centered health care?"

At the heart of CARE is a novel collaborative filtering method that captures patient similarities and produces personalized disease risk profiles for individuals. Using what is known as Big Data science, the system generates predictions focused on other diseases that are based on Big Data from similar patients.

"In its most conservative use, the CARE rankings can provide reminders for conditions that busy doctors may have overlooked," Chawla said. "Utilized to its full potential, CARE can be used to explore broader disease histories, suggest previously unconsidered concerns, and facilitate discussion about early testing and prevention, as well as wellness strategies that may ring a more familiar bell with an individual and are essentially doable.

"We believe that our work can lead to reduced re-admission rates, improved quality of care ratings and can demonstrate meaningful use, impact personal and population health, and push forward the discussion and impact on the patient-centered paradigm."

Chawla points out that the core premise of CARE is centered on patient empowerment and patient engagement.

"Imagine visiting your physician's office with a list of concerns and questions," he said. "What if you could walk out of the office with a personalized assessment of your health, along with a list of personalized and important lifestyle change recommendations based on your predicted health risks? What if your physician was afforded a limitless experience to gauge the impact of your disease toward developing other diseases in the future? What if you could find out that there are other patients similar to you not only with respect to major symptoms, but also with respect to rare issues that have puzzled your doctor? What if you could have the experience of others at your fingertips and fathom the lifestyle changes warranted for mitigating diseases?"

Chawla believes the timing is right for CARE given changes in health care, reimbursement, reform, meaningful use of electronic health care data and a mandate for patient-centered outcomes.

"The industry is seeing a move toward health and wellbeing and how that can be personalized to an individual," he said. "There is an increased focus on preventative care, wellbeing and reducing re-admission rates in the hospital. This system can help bend the cost curve."

CARE has been awarded a U.S. patent.


'/>"/>

Contact: Nitesh Chawla
nchawla@nd.edu
574-631-1090
University of Notre Dame
Source:Eurekalert

Related biology news :

1. Notre Dame study finds Asian carp DNA not widespread in the Great Lakes
2. Notre Dame researcher is studying role small dams play in pollution control
3. Notre Dame researchers are using new technologies to combat invasive species
4. Notre Dame research may have important implications for combating diabetes
5. Cargill expands support of Notre Dame Haiti Program
6. Notre Dame research reveals migrating Great Lakes salmon carry contaminants upstream
7. Notre Dame research could improve sustainability and cost effectiveness of wastewater treatment
8. Notre Dame research could provide new insights into tuberculosis and other diseases
9. Notre Dame researcher is shedding light on how jaws evolve
10. Notre Dame establishes professorships in adult stem cell research
11. Notre Dame researchers using novel method to combat malaria drug resistance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2017)... Research and Markets has announced the addition ... and Commercial Aspects" to their offering. ... Biomarkers play an ... for selection of treatment as well for monitoring the results. ... in modern medicine. Biochip/microarray technologies and next generation sequencing are ...
(Date:2/8/2017)... About Voice Recognition Biometrics Voice recognition biometrics ... a stored voiceprint template. Acoustic features of an ... are compared to distinguish between individual voices. Voice ... PCs already have a microphone and can authenticate ... are most likely to be deployed in telephone-based ...
(Date:2/8/2017)... -- Report Highlights ... The global synthetic-biology market reached nearly $3.9 billion ... at a compound annual growth rate (CAGR) of 24.0% through ... markets for synthetic biology. - Analyses of global market trends, ... compound annual growth rates (CAGRs) through 2021. - Coverage of ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... PHILADELPHIA , Feb. 16, 2017  ImMAGE Biotherapeutics (OTCMKTS: ... immune system to find a better treatment for triple negative ... Start in France program. ... is an accelerator designed to help entrepreneurs grow their business ... was one of eight American companies selected to complete an ...
(Date:2/16/2017)... 2017  ArmaGen, Inc., a privately held biotechnology ... severe neurological disorders, today reported preliminary evidence of ... company,s investigational therapy for the treatment of Hurler ... I, or MPS I). The initial results from ... today at the 13 th annual WORLD ...
(Date:2/16/2017)... HOLLISTON, Mass. , Feb. 16, 2017   ... or the "Company"), a biotechnology company developing bioengineered organ ... the esophagus, bronchus and trachea, announced today the closing ... offering of 20,000,000 shares of common stock and warrants ... gross proceeds of $8.0 million. The offering was priced ...
(Date:2/16/2017)...  Dermata Therapeutics, LLC, a biotechnology company developing ... of dermatological diseases, today announced it has completed ... into a $5 million credit facility with Silicon ... capital for general corporate purposes to further Dermata,s ... of serious diseases treated by dermatologists.   ...
Breaking Biology Technology: